Novocure up after Japan approves lung cancer treatment

NovoCure

15/09/2025 13:30

** Shares of cancer therapy maker Novocure NVCR.O up 1.4% at $12.32 premarket

** Company says Japan's health ministry has approved NVCR's Optune Lua for patients with advanced or recurrent non-small cell lung cancer who have not responded to platinum-based chemotherapy

** The treatment uses Tumor Treating Fields, or electric fields, through a portable device, Optune Lua, placed on the skin near the tumor that targets cancer cells while sparing most nearby healthy cells

** The device was approved by the U.S. FDA in October 2024

** As of last close, stock down 59.2% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))